Artificial Intelligence is Reshaping Pharmacovigilance – But Are You Ready?
With over 1.5 million adverse drug reactions reported annually in the EU alone, the pressure on pharmacovigilance systems has never been greater. Could artificial intelligence (AI) be the answer?
In this episode of International Pharma Talks, Dr. Diogo Sousa-Martins, Founder and President of ELS Group, discusses how AI is transforming the landscape of drug safety, and what pharmaceutical companies must do to stay ahead.
From automation and real-time signal detection to regulatory hurdles and ethical challenges, we break down how AI is redefining the future of pharmacovigilance and what that means for compliance, patient safety, and innovation.
You’ll learn more about:
How AI enhances adverse event detection across large, unstructured data sources
Compliance requirements under EMA, FDA, and ISO standards
Why early-stage integration of AI is a strategic (not optional) investment
How companies can adopt scalable, cost-effective AI solutions without compromising compliance
The integration of AI into pharmacovigilance isn’t a distant possibility, it’s an urgent priority. But real transformation requires more than just algorithms. It demands strategic planning, regulatory alignment, and expert guidance.
Tune in now to understand how your company can use AI to enhance pharmacovigilance performance, reduce risk, and strengthen patient trust.
Learn more at els-solutions.com/This episode was recorded in 2025. Some of the data discussed may have changed since then. This podcast has been prepared using various bibliographic sources. The opinions expressed reflect the professional experiences of ELS members and referenced material.